1. HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007). Kalkeri, R., J. Peng, C. Huang, Z. Cai, R.G. Ptak, and M.J. Suto. Advances in Virology, 2020. 2020: 8844061. PMID[33110426]. PMCID[PMC7582060].
[PubMed]. HBV_10_2020.
2. Development of an in Vivo Delivery System for Crispr/Cas9-Mediated Targeting of Hepatitis B Virus cccDNA. Kayesh, M.E.H., Y. Amako, M.A. Hashem, S. Murakami, S. Ogawa, N. Yamamoto, T. Hifumi, N. Miyoshi, M. Sugiyama, Y. Tanaka, M. Mizokami, M. Kohara, and K. Tsukiyama-Kohara. Virus Research, 2020. 290: 198191. PMID[33049308].
[PubMed]. HBV_10_2020.
3. Potential Molecular Mechanisms of Plantain in the Treatment of Gout and Hyperuricemia Based on Network Pharmacology. Liu, P., H. Xu, Y. Shi, L. Deng, and X. Chen. Evidenced Based Complementary and Alternative Medicine, 2020. 2020: 3023127. PMID[33149752]. PMCID[PMC7603577].
[PubMed]. HBV_10_2020.
4. Bifunctional Macromolecule Activating Both OX40 and Interferon-Α Signaling Displays Potent Therapeutic Effects in Mouse HBV and Tumor Models. Mo, S., L. Gu, W. Xu, J. Liu, D. Ding, Z. Wang, J. Yang, L. Kong, and Y. Zhao. International Immunopharmacology, 2020. 89(Pt B): 107099. PMID[33091819].
[PubMed]. HBV_10_2020.
5. Briarane-type Diterpenoids from a Gorgonian Coral Ellisella sp. With anti-HBV Activities. Wu, J., X. Li, X. Guo, Z. Cheng, J. Meng, W. Cheng, and W. Lin. Bioorganic Chemistry, 2020. 105: 104423. PMID[33160223].
[PubMed]. HBV_10_2020.
Patent Citations
6. Preparation of Oxoimidazopyrazine Derivatives for Use as Antiviral Agents. Vendeville, S., P.J.-M.B. Raboisson, and Y. Debing. Patent. 2020. 2020-US28349 2020214728: 333pp.
[Patent]. HBV_10_2020.
7. Pyrrole Compounds as Antiviral Agents for the Treatment of Hepatitis B and D and Their Preparation. Vendeville, S., D.B. Smith, L. Beigelman, V. Serebryany, R.F. Schinazi, F. Amblard, and L. Bassit. Patent. 2020. 2020-US26116 2020205934: 145pp.
[Patent]. HBV_10_2020.